Read here for an analysis of Boise Cascade (BCC) stock's market resilience, high vertical integration, and financial outlook ...

The iShares MSCI Chile ETF (ECH) is outperforming emerging markets and showing breakout potential ahead of elections. See ...

Kyverna Therapeutics (KYTX) is rated a strong buy with promising KYV-101 Phase 2 data and near-term catalysts. Read here for ...

Meta Platforms delivers long-term compounding, AI monetization, strong Q3 growth and higher CAPEX with upside potential.

The Fed continues to navigate a challenging backdrop: a steadily cooling labor market alongside inflation that remains ...

Pfizer beats Q3 estimates, raises FY guidance, acquires Metsera for obesity drugs, and offers a 7% yield. Read here for an ...

HF Foods Group is a buy, with 50% upside potential despite dilution risks. HFFG is a buy for investors comfortable with ...

Wasatch highlights Q3 winners Medpace, Fabrinet, and Nova, while exiting Inspire. See how conviction, AI exposure, and ...

Arch Capital Group shows strong fundamentals, solid Q3 benefits, steady profitability and disciplined buybacks at value ...

ORIX Corp stock is rated a Buy after a strong Q2, a 70% profit surge, and raised FY26 guidance. Here's what investors need to ...

Explore the Wasatch U.S. Select Fund's Q3 2025 results, including underperformance vs. its benchmark and analysis of key ...

Adam Gould, Global Head of Equities at Tradeweb, said, “Our European ETF platform delivered another strong performance in ...